ライフサイエンスコーパス: type O

1 s than 50% of the species present (community type O).

2 2.03-3.54) compared with nonsmokers of blood type O.

3 96.4%) were White, and 104 (41.6%) had blood type O.

4 edemptions were among individuals with blood type O.

5 myocardial infarction associated with blood type O.

6 splants on average, more if the NDD is blood type O.

7 lowing exposure to either Abca4(-/-) or wild-type OS.

8 owed by a temperature shift to 37 degrees C, type O(1)C3056R-KGE colocalized with caveolin-1, while O

9 Using a genetically engineered variant of type O(1)Campos (O(1)C3056R) which can utilize both inte

10 The rNV VLPs hemagglutinated all human type O (11 of 11), A (9 of 9), and AB (4 of 4) RBCs; how

11 s results in GBS, and 1 of 158 Campylobacter type O:19 infections results in GBS.

12 Accordingly, the dioxygenase-type O(2) activation and O-atom transfer cycling are a d

13 of new multielectron catalysts for oxygenase-type O(2) activation, as well as the microscopic reverse

14 r (N-acetylglucosamine or GlcNAc), show wild-type O(2) dependence of culmination, cells lacking AgtA,

15 can American (23 777 [47.0%]), had ABO blood type O (22 879 [45.2%]), and were Rhesus factor positive

16 ependent downregulation of forkhead homeobox type O 3 and hyperproliferation.

17 s. 25 kg/m2, p = .03), less frequently blood type O (36% vs. 80%, p < .001), and had higher eGFR (99

18 years), and most were male (90%), and blood type O (79%).

19 ian wait times were 108 days (<=25 kg, blood type O), 80 days (<=25 kg, non-O), 47 days (>25 kg, O),

20 icipants by genotype-derived serologic blood type (O, A, AB, and B).

21 Compared with type O, A and B blood types have higher risk of antepart

22 ation assays; GST-VP8* P[11] hemagglutinates type O, A, and B red blood cells as well as pooled umbil

23 The incidence rates for blood types O, A, AB, and B were 28.9, 39.9, 41.8, and 44.5 ca

24 nal antibody was shown to recognize the wild-type O-acetylated CPS, but not the CPS of the mynC mutan

25 In a given cell type, O-acetylation can also be specific to a particular

26 n an acquired ability to infect CHO cells by type O and Asia-1 FMDV.

27 Patients with ABO blood type O and B have smaller chances.

28 ths after KPD entry included recipient blood type O and calculated panel reactive antibodies >=98%.

29 would be different between donors with blood type O and those with non-O.

30 n pathway and can produce well defined human-type O- and N-linked glycans on recombinant therapeutics

31 ation, and global deprotection of all benzyl-type O- and N-protecting groups furnished the desired la

32 hat it lacked the terminal sugar of the wild-type O antigen, 2,3,4-tri-O-methylfucose.

33 omotrimeric tailspike that cleaves the O18A1 type O antigen.

34 ype (4.9% stillbirths, 3.0% live births) (vs type O; AOR, 1.96 [95% CI, 1.16-3.30]); history of drug

35 lation followed by an intramolecular Ullmann-type O-arylation.

36 -list mortality; however, infants with blood type O assigned an ABO-I listing strategy were more like

37 <0.003), UNOS status I and II (P<0.007), ABO type O, B, and AB (P<0.03), and reduced-size/split liver

38 bAC) 103 (7%), alpha thalassaemia 438 (28%), type O blood group 621 (40%), and G6PD deficiency 72 (9%

39 re COVID-19 illness or death associated with type O blood group versus all others (aRR, 0.87 [CI, 0.7

40 Candidates listed for LTx with type O blood had better clinical status at evaluation, b

41 The 308 candidates with type O blood waited longer for LTx (median 109 days) tha

42 Type-O blood candidates had significant decline in progn

43 accomplishes the conversion of regular human type-O blood into a potential blood substitute for the r

44 nts) and deaths would have shifted away from type O candidates (4.6 [95% CI: 2.7, 6.8] fewer deaths).

45 wever, transplants would have shifted toward type O candidates (57.8 [95% CI: 35.1, 80.9] additional

46 al of increasing transplant access for blood type O candidates after an error was discovered in the s

47 ed mortality incidence (95% CI) decreased in type O candidates from 3.6% (3.0%, 4.3%) premodification

48 LTx candidates with other blood types, blood type O candidates have longer waiting times and higher p

49 The transplant rate was lowest for type O candidates in both eras, but significantly increa

50 pe-compatible transplant is a gold standard, type O candidates might benefit from listing for A2 dono

51 A total of 61.1% of type O candidates were listed as A2 donors, with conside

52 2 donors could improve waitlist outcomes for type O candidates.

53 Following CD policy, blood type-O candidates had lower incidence of transplantation

54 ct of initial policy implementation on blood type-O candidates has not been rigorously evaluated.

55 Blood type-O candidates were more likely Hispanic and 'Other'

56 ificantly associated with having a community type O cervicovaginal microbiota.

57 VWF binding rate are significantly lower for type O compared with non-O platelets.

58 2 and protein tyrosine phosphatase, receptor type, O cooperated with the v-raf murine sarcoma viral o

59 s hypothesis, we perfused blood from healthy type O donors (n = 33) or non-O donors (n = 54) over poo

60 Our results demonstrate that platelets from type O donors interact less with VWF at arterial shear t

61 lturing NELL1 knockout sarcoma cells on wild-type OS-enriched matricellular proteins reversed the phe

62 the H-antigen trisaccharide from human blood type O erythrocytes, at 1.67 angstrom resolution.

63 orm of protein tyrosine phosphatase receptor type O expressed predominantly in hematopoietic cells, i

64 se that the lower polymerase fidelity of the type O FMDV could contribute to its dominance worldwide.

65 es evidence that higher genetic diversity of type O FMDV could increase both virulence and transmissi

66 Given that type O FMDV exhibits the highest genetic diversity among

67 5% CI 1.27-51.44], p=0.025; OR for community type O for BRCA1 mutation carriers aged <35 years in the

68 BRCA1 mutation status (eg, OR for community type O for cases aged <40 years in the ovarian cancer se

69 Here, we produced mucin-type O-GalNAc and core 1 O-linked glycan structures on r

70 is the Tn antigen (CD175), which is a mucin-type O-GalNAc-Ser/Thr/Tyr glycan in membrane and secrete

71 s large-scale mapping of site-specific mucin-type O-GalNAcylation sites.

72 n, the protein-tyrosine phosphatase receptor type O gene, PTPRO, was frequently methylated in right-s

73 Mucin-type O-gly co sy la tion is initiated by a large family

74 Pathway enrichment analyses show that mucin-type O-glycan biosynthesis and cardiomyocyte adrenergic

75 l transferases (ppGalNAc Ts) initiates mucin-type O-glycan biosynthesis at serine and threonine.

76 Mucin-type O-glycan biosynthesis is regulated by the family of

77 alNAcalpha1-Ser/Thr (T antigen) during mucin type O-glycan biosynthesis.

78 TCR avidities, perforin levels, and surface type O-glycan levels indicative of mature CD8(+) T cell

79 e2 O-glycan is presumably an essential mucin-type O-glycan structure found in both molecules in vivo.

80 hether such differential expression of mucin-type O-glycan structures has physiological significance

81 c-R is the precursor for many extended mucin-type O-glycan structures in animal cell surface and secr

82 e first to clearly identify functional mucin-type O-glycan structures modulating cell surface express

83 Mucin-type O-glycan structures were analyzed at both stages by

84 Here, we compared expression of mucin-type O-glycan synthases from proliferating and different

85 9, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.

86 -type N-glycans, a novel HexNAc-GalNAc-mucin-type O-glycan, and Tn-antigen; identified the glycosyltr

87 now identify a sulfated extended core1 mucin-type O-glycan, Gal beta 1-->4(sulfo-->6)GlcNAc beta 1-->

88 Mucin-type O-glycans (O-glycans) are highly expressed in vascu

89 muscle-specific domain (MSD) to which mucin type O-glycans are attached.

90 Mucin-type O-glycans are classified according to their core st

91 s (cores one to eight), from which all mucin-type O-glycans are derived.

92 rate ligands that reveal how host cell mucin-type O-glycans are recognized and allow a structure-guid

93 talytic preference for core 2-branched mucin-type O-glycans as found in natural L-selectin counterrec

94 ct binding preferences for sialylated GalNAc-type O-glycans but exhibit selectivity for patterns of O

95 Poly-N-acetyllactosamines in mucin-type O-glycans can be formed in core 2 branched oligosac

96 Mucin-type O-glycans could be imaged as early as 7 hours postf

97 Mucin-type O-glycans form one of the most abundant and complex

98 gen), the precursor structure for most mucin-type O-glycans in a wide variety of glycoproteins.

99 This study identified the most common mucin-type O-glycans in human tears and their expected biosynt

100 Characterization of mucin-type O-glycans linked to serine/threonine of glycoprotei

101 Mucin-type O-glycans on glycoproteins are pivotal for biology

102 one Cosmc regulate the biosynthesis of mucin type O-glycans on glycoproteins, and evidence suggests t

103 ults indicate that polysialic acid and mucin type O-glycans on NCAM differentially regulate myoblast

104 Mucin-type O-glycans play key roles in many cellular processes

105 ive method used to amplify and profile mucin-type O-glycans synthesized by living cells.

106 tructural evidence for a novel type of mucin-type O-glycans that is strictly specific for LacdiNAc te

107 a pivotal role in the biosynthesis of mucin-type O-glycans that serve as ligands in cell adhesion.

108 cular surface epithelium to synthesize mucin-type O-glycans to maintain a wet-surface phenotype.

109 icits in aged mice by restoring core 1 mucin-type O-glycans to the brain endothelium using adeno-asso

110 However, the presence of clustered mucin-type O-glycans together with N-glycans makes the determi

111 Mucin type O-glycans with core 2 branches are distinct from no

112 O-GalNAc glycans, also known as mucin-type O-glycans, are primary constituents of mucins on va

113 se (C1GALT1) controls the formation of mucin-type O-glycans, far overlooked and underestimated in can

114 Finally, we apply our method on mucin-type O-glycans, gangliosides, and site-specific composit

115 gates (O-fucose, O-mannose, N-glycans, mucin-type O-glycans, proteoglycans, glycosphingolipids), focu

116 -Ser/Thr) is an important precursor of mucin-type O-glycans.

117 attachment to the peptide backbone in mucin-type O-glycans.

118 cleaves the initial alpha-GalNAc from mucin-type O-glycans.

119 tion, and a combination of core 1 and core 2 type O-glycans.

120 amental challenges for the analysis of mucin-type O-glycans.

121 lactosamine moieties for inhibition of mucin-type O-glycans.

122 predicted to act in the synthesis of core-1 type O-glycans.

123 nuclear O-Fuc-type and cell surface Glc-Fuc-type O-glycans; and showed that they are important for i

124 Beyond the mucin-type O-glycopeptides discussed here, O-Pair Search also

125 d to enrich GlcNAc-capped N-glycans or mucin type O-glycopeptides from complex samples in glycomics a

126 core 2 GlcNAc transferase acting on a mucin-type O-glycoprotein displayed increased galectin-3 bindi

127 ere, we report a comprehensive map of GalNAc-type O-glycoproteins (>800) and O-glycosites (>4000) fro

128 Mucin-type O-glycoproteins are present abundantly in bone, whe

129 amine residues, which are present in a mucin-type O-glycosidic linkage.

130 We focused on GalNAc-type O-glycosylation and selected the GalNAc-T11 isoenzy

131 inyl transferases (GalNAc-Ts) initiate mucin type O-glycosylation by catalyzing the transfer of N-ace

132 mary, this study demonstrates that mammalian type O-glycosylation can be established in plants and th

133 understanding of the diverse roles of mucin-type O-glycosylation during eukaryotic development.

134 Here we show that the N-acetylgalactosamine-type O-glycosylation enzyme GALNT11 is crucial to such d

135 reviously unrecognized requirement for mucin-type O-glycosylation in epithelial tube integrity and ha

136 have demonstrated essential roles for mucin-type O-glycosylation in protein secretion, stability, pr

137 Mucin type O-glycosylation is a highly conserved form of post-

138 Mucin-type O-glycosylation is an essential post-translational

139 Mucin-type O-glycosylation is an evolutionarily conserved prot

140 Mucin-type O-glycosylation is an important post-translational

141 The initiation of mucin-type O-glycosylation is catalyzed by a family of UDP-Gal

142 Mucin-type O-glycosylation is initiated by a family of UDP-Gal

143 Mammalian mucin-type O-glycosylation is initiated by a large family of a

144 Mucin type O-glycosylation is initiated by a large family of p

145 Mucin-type O-glycosylation is initiated by a large family of U

146 Mucin-type O-glycosylation represents a major form of post-tra

147 esults and can be applied to a complex mucin-type O-glycosylation site analysis of other glycoprotein

148 ific inhibitors, and the prediction of mucin-type O-glycosylation sites.

149 Since in mucin type O-glycosylation sugars are added individually and s

150 In summary, stably engineered mammalian type O-glycosylation was established in transgenic plant

151 Abnormal N- and mucin type O-glycosylation was found on serum proteins, and re

152 Abnormal N- and/or mucin type O-glycosylation was observed in all patients tested

153 inyl-transferases (GalNAc-Ts) initiate mucin-type O-glycosylation, an abundant and complex posttransl

154 ted individuals showed abnormal N- and mucin-type O-glycosylation, and mass spectrometry indicated re

155 l-D-galactosamine (GalNAc) (core-1) in mucin type O-glycosylation, and thus terminates chain extensio

156 (EC 2.4.1.41) of enzymes that initiate mucin-type O-glycosylation, are structurally composed of a cat

157 ransferases (GalNAc-Ts), that initiate mucin-type O-glycosylation, consist of a catalytic and a lecti

158 Long term inhibition of mucin-type O-glycosylation, sialylation, or sulfation altered

159 Because plants are devoid of GalNAc-type O-glycosylation, we have assessed requirements for

160 oat, can now be ascribed to defects in mucin-type O-glycosylation.

161 of up to 20 transferases that initiate mucin-type O-glycosylation.

162 ate the involvement of GalNAc-type (or mucin-type) O-glycosylation in EMT process, induced with trans

163 Mucin-type (N-acetylgalactosamine [GalNAc]-type) O-glycosylation is found in eumetazoan cells but a

164 Mucin-type-O-glycosylation on proteins is integrally involved

165 ycosylation of the protein CST1 by the mucin-type O-glycosyltransferase T. gondii (Txg) GalNAc-T3 inf

166 ortality due to the broader compatibility of type O grafts.

167 (302) or Q(375) in VA387 affected binding to type O HBGA only, while switch mutants with three amino

168 m MOH to VA387 resulted in a weak binding to type O HBGAs.

169 risk of moderate to severe ARDS relative to type O in all 3 populations.

170 Blood type O is associated with a lower risk of myocardial inf

171 bling species Paramecium septaurelia, mating type O is determined by coding-sequence deletions in a d

172 e transmembrane protein mtA, and the default type O is determined during development by scnRNA-depend

173 The pig type O isolate was not closely related to that recovered

174 Mucin-type O-linked glycoproteins are involved in a variety of

175 y numerous cell types and installed on mucin-type O-linked glycoproteins by the ppGalNAcTs.

176 n addition, GalNAz efficiently labeled mucin-type O-linked glycoproteins expressed at endogenous leve

177 erein we present a method for labeling mucin-type O-linked glycoproteins with a unique chemical tag,

178 The ability to label mucin-type O-linked glycoproteins with chemical tags should fa

179 in (also known as proteoglycan 4) is a mucin-type O-linked glycosylated biological lubricant implicat

180 the ppGalNAcTs makes the prediction of mucin-type O-linked glycosylation difficult based on primary s

181 Changes in mucin-type O-linked glycosylation in breast cancer can result

182 aNTases) is responsible for initiating mucin-type O-linked glycosylation in higher eukaryotes.

183 ere, we provide the first example that mucin-type O-linked glycosylation is involved in a development

184 Our studies suggest that mucin-type O-linked glycosylation may be required for normal d

185 ium, but not Plasmodium, possesses an animal-type O-linked glycosylation pathway, along with >30 pred

186 In mucin-type O-linked glycosylation these changes can result in

187 hanistically similar to that of animal mucin type O-linked glycosylation, except that it occurs in th

188 Mucin-type O-linked oligosaccharides (O-glycans) are primary c

189 Mucin-type O-linked oligosaccharides were directly released by

190 ows the structural characterization of mucin-type O-linked oligosaccharides.

191 tion of the GALNT enzyme in initiating mucin type O-linked protein glycosylation.

192 (ppGaNTases) initiate the formation of mucin-type, O-linked glycans by catalyzing the transfer of alp

193 Among different types, O-linked or mucin-type oligosaccharides are intim

194 Blood type O liver transplantation (LT) candidates in the Unit

195 tcomes of listing for A2 donors among 67 756 type O LT candidates listed between 2010 and 2023 using

196 r older had a higher prevalence of community type O microbiota (81 [61%] of 133 ovarian cancer cases

197 e stronger the association between community type O microbiota and ovarian cancer or BRCA1 mutation s

198 ears were also more likely to have community type O microbiota than age-matched controls (OR 2.79 [95

199 significantly higher prevalence of community type O microbiota than did age-matched controls under a

200 were more blood type O recipients than blood type O NDDs participating.

201 The 40 blood type O NDDs triggered a mean chain length of 6.0 (median

202 n = 90) was greater than the number of blood type O-non-directed donors (n = 32) initiating chains.

203 d with the MBL genotype (A/A indicating wild type, O/O indicating homozygous for MBL structural-gene

204 Especially highly sensitized and blood type O patients benefit.

205 od type, but no correlation was observed for type O patients, suggesting that von Willebrand factor (

206 The number of blood type O-patients receiving a transplant (n = 90) was grea

207 Further analyses identified a class II-type O-phosphoseryl-tRNA synthetase (SepRS) and Sep-tRNA

208 We demonstrate for the first time that type O platelets travel farther at greater speeds before

209 he rat protein tyrosine phosphatase receptor type O (PTPRO) and one amplified gene as rat C-MYC.

210 ne for protein tyrosine phosphatase receptor-type O (PTPRO) in primary and established rat hepatomas.

211 elated)] and the type III RPTP, PTP receptor type O (PTPRO), have been implicated in the regulation o

212 Protein tyrosine phosphatase receptor type O (PTPRO), which is required for Eph receptor-depen

213 orm of protein-tyrosine phosphatase receptor-type O (PTPROt) is specifically expressed in hematopoiet

214 ype 2 antibody inhibited rNV VLP HA of human type O RBCs.

215 unctions as the rNV VLP HA receptor on human type O RBCs.

216 antigens also inhibited rNV VLP HA of human type O RBCs.

217 There were more blood type O recipients than blood type O NDDs participating.

218 One hundred thirty-three blood type O recipients were transplanted.

219 plants performed prior to CD, 48% were blood type-O recipients compared to 40% post-CD, representing

220 80.5% for blood types-A, B, or AB and blood type-O, respectively, P = .57).

221 RBCs from healthy universal donors (type O, Rh negative) were incubated with SLE or control

222 Incubation of RBC from universal donors (type O, Rh negative) with trauma sera (n = 10) promoted

223 s indicate that in vitro cultivation of FMDV type O selects viruses that bind to heparin and that vir

224 n those with blood type O; The <25 kg, blood type O subgroup experiences longer wait times and higher

225 lood, Dunne et al report that platelets from type O subjects bound poorly to von Willebrand factor (V

226 Compared with blood type O, the ORs for pancreatic cancer in subjects with t

227 in candidates <25 kg and in those with blood type O; The <25 kg, blood type O subgroup experiences lo

228 k from MST1/2 via BUB3 and forkhead homeobox type O to the abnormal proliferation and survival of pul

229 to 40% post-CD, representing 138 fewer blood type-O transplants than expected.

230 developmentally regulated PTP, PTP receptor-type O truncated (PTPROt).

231 a nonischemic cause of heart failure, blood type O, United Network for Organ Sharing status 2 at lis

232 In contrast, both type O viruses utilized alpha(V)beta(6) and alpha(V)beta

233 exchanges to ensure that the standard blood type O wait-list candidates are made better off.

234 problematic because it harms standard blood type O wait-list candidates who already have the longest

235 ncreased among AB and B types, compared with type O, while risk of death was increased for type AB an

236 Transplantation of bone marrow from wild-type o XBP1ecko mice could also slightly improve the foo